

Luca Sigalotti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3082897/publications.pdf>

Version: 2024-02-01

55
papers

2,915
citations

172457

29
h-index

182427

51
g-index

60
all docs

60
docs citations

60
times ranked

4343
citing authors

#	ARTICLE	IF	CITATIONS
1	Loss of Spry1 reduces growth of BRAFV600-mutant cutaneous melanoma and improves response to targeted therapy. <i>Cell Death and Disease</i> , 2020, 11, 392.	6.3	14
2	Guadecitabine Plus Ipilimumab in Unresectable Melanoma: The NIBIT-M4 Clinical Trial. <i>Clinical Cancer Research</i> , 2019, 25, 7351-7362.	7.0	61
3	Quantitative Methylation-Specific PCR: A Simple Method for Studying Epigenetic Modifications of Cell-Free DNA. <i>Methods in Molecular Biology</i> , 2019, 1909, 137-162.	0.9	8
4	Safety and immunobiological activity of guadecitabine sequenced with ipilimumab in metastatic melanoma patients: The phase Ib NIBIT-M4 study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2549-2549.	1.6	0
5	Abstract CT059: Epigenetic tumor remodelling to improve the efficacy of immune checkpoint blockade: the NIBIT-M4 clinical trial. , 2018, , .		3
6	Prognostic significance of LINE-1 hypomethylation in oropharyngeal squamous cell carcinoma. <i>Clinical Epigenetics</i> , 2017, 9, 58.	4.1	32
7	Abstract 1196: Epigenetic drugs modulate long noncoding RNAs expression in BRAF inhibitor-resistant melanoma. , 2017, , .		0
8	Toll-Like Receptor 1/2 and 5 Ligands Enhance the Expression of Cyclin D1 and D3 and Induce Proliferation in Mantle Cell Lymphoma. <i>PLoS ONE</i> , 2016, 11, e0153823.	2.5	15
9	Epimutational profile of hematologic malignancies as attractive target for new epigenetic therapies. <i>Oncotarget</i> , 2016, 7, 57327-57350.	1.8	24
10	Antitumor activity of epigenetic immunomodulation combined with CTLA-4 blockade in syngeneic mouse models. <i>Oncimmunology</i> , 2015, 4, e1019978.	4.6	61
11	Molecular Pathways: At the Crossroads of Cancer Epigenetics and Immunotherapy. <i>Clinical Cancer Research</i> , 2015, 21, 4040-4047.	7.0	89
12	Epigenetic Markers of Prognosis in Melanoma. <i>Methods in Molecular Biology</i> , 2014, 1102, 481-499.	0.9	6
13	Epigenetic drugs as immunomodulators for combination therapies in solid tumors. , 2014, 142, 339-350.		92
14	Immunomodulatory activity of SGI-110, a 5-aza-2â€²-deoxycytidine-containing demethylating dinucleotide. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 605-614.	4.2	61
15	Epigenetics of melanoma: implications for immune-based therapies. <i>Immunotherapy</i> , 2013, 5, 1103-1116.	2.0	18
16	Epigenetic remodelling of gene expression profiles of neoplastic and normal tissues: immunotherapeutic implications. <i>British Journal of Cancer</i> , 2012, 107, 1116-1124.	6.4	20
17	Whole genome methylation profiles as independent markers of survival in stage IIIC melanoma patients. <i>Journal of Translational Medicine</i> , 2012, 10, 185.	4.4	49
18	The biology of cancer testis antigens: Putative function, regulation and therapeutic potential. <i>Molecular Oncology</i> , 2011, 5, 164-182.	4.6	281

#	ARTICLE	IF	CITATIONS
19	Methylation levels of the "long interspersed nucleotide element-1" repetitive sequences predict survival of melanoma patients. <i>Journal of Translational Medicine</i> , 2011, 9, 78.	4.4	52
20	Expression and regulation of B7 α 3 immunoregulatory receptor, in human mesothelial and mesothelioma cells: Immunotherapeutic implications. <i>Journal of Cellular Physiology</i> , 2011, 226, 2595-2600.	4.1	17
21	Stability of BRAF V600E mutation in metastatic melanoma: new insights for therapeutic success?. <i>British Journal of Cancer</i> , 2011, 105, 327-328.	6.4	13
22	Cancer testis antigens and melanoma stem cells: new promises for therapeutic intervention. <i>Cancer Immunology, Immunotherapy</i> , 2010, 59, 487-488.	4.2	5
23	Clinical Studies With Anti α CTLA-4 Antibodies in Non-melanoma Indications. <i>Seminars in Oncology</i> , 2010, 37, 460-467.	2.2	52
24	Epigenetically regulated clonal heritability of CTA expression profiles in human melanoma. <i>Journal of Cellular Physiology</i> , 2010, 223, 352-358.	4.1	19
25	CXCR6, a Newly Defined Biomarker of Tissue-Specific Stem Cell Asymmetric Self-Renewal, Identifies More Aggressive Human Melanoma Cancer Stem Cells. <i>PLoS ONE</i> , 2010, 5, e15183.	2.5	65
26	Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategies. <i>Journal of Translational Medicine</i> , 2010, 8, 56.	4.4	94
27	Epigenetically regulated tumor-associated antigens in melanoma. <i>Expert Review of Dermatology</i> , 2009, 4, 145-154.	0.3	1
28	Cancer testis antigens in human melanoma stem cells: Expression, distribution, and methylation status. <i>Journal of Cellular Physiology</i> , 2008, 215, 287-291.	4.1	56
29	Functional Up-regulation of Human Leukocyte Antigen Class I Antigens Expression by 5-aza-2 α -deoxycytidine in Cutaneous Melanoma: Immunotherapeutic Implications. <i>Clinical Cancer Research</i> , 2007, 13, 3333-3338.	7.0	120
30	5-AZA-2 α -Deoxycytidine in Cancer Immunotherapy: A Mouse to Man Story. <i>Cancer Research</i> , 2007, 67, 2900-2900.	0.9	21
31	Epigenetic drugs as pleiotropic agents in cancer treatment: Biomolecular aspects and clinical applications. <i>Journal of Cellular Physiology</i> , 2007, 212, 330-344.	4.1	124
32	Missense mutations in Desmocollin-2 N-terminus, associated with arrhythmogenic right ventricular cardiomyopathy, affect intracellular localization of desmocollin-2 in vitro. <i>BMC Medical Genetics</i> , 2007, 8, 65.	2.1	61
33	OR.19. Can Epigenetics Have a Clinical Impact in the Treatment of Melanoma?. <i>Clinical Immunology</i> , 2006, 119, S11.	3.2	0
34	Phenotypic and functional changes of human melanoma xenografts induced by DNA hypomethylation: Immunotherapeutic implications. <i>Journal of Cellular Physiology</i> , 2006, 207, 58-66.	4.1	52
35	Epigenetic Modulation of Solid Tumors as a Novel Approach for Cancer Immunotherapy. <i>Seminars in Oncology</i> , 2005, 32, 473-478.	2.2	44
36	Epigenetic Immunomodulation of Hematopoietic Malignancies. <i>Seminars in Oncology</i> , 2005, 32, 503-510.	2.2	17

#	ARTICLE	IF	CITATIONS
37	Methylation-regulated expression of cancer testis antigens in primary effusion lymphoma: Immunotherapeutic implications. <i>Journal of Cellular Physiology</i> , 2005, 202, 474-477.	4.1	23
38	Intratumor Heterogeneity of Cancer/Testis Antigens Expression in Human Cutaneous Melanoma Is Methylation-Regulated and Functionally Reverted by 5-Aza-2'-deoxycytidine. <i>Cancer Research</i> , 2004, 64, 9167-9171.	0.9	193
39	Methylation-regulated expression of HLA class I antigens in melanoma. <i>International Journal of Cancer</i> , 2003, 105, 430-431.	5.1	41
40	Differential levels of soluble endoglin (CD105) in myeloid malignancies. <i>Journal of Cellular Physiology</i> , 2003, 194, 171-175.	4.1	48
41	Epigenetic targets for immune intervention in human malignancies. <i>Oncogene</i> , 2003, 22, 6484-6488.	5.9	68
42	Emerging Role of Endoglin (CD105) as a Marker of Angiogenesis with Clinical Potential in Human Malignancies. <i>Current Cancer Drug Targets</i> , 2003, 3, 427-432.	1.6	83
43	Analysis of Cancer/Testis Antigens in Sporadic Medullary Thyroid Carcinoma: Expression and Humoral Response to NY-ESO-1. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 748-754.	3.6	61
44	5-Aza-2'-deoxycytidine (decitabine) treatment of hematopoietic malignancies: a multimechanism therapeutic approach?. <i>Blood</i> , 2003, 101, 4644-4646.	1.4	78
45	Cancer testis antigens expression in mesothelioma: role of DNA methylation and bioimmunotherapeutic implications. <i>British Journal of Cancer</i> , 2002, 86, 979-982.	6.4	83
46	Promoter Methylation Controls the Expression of MAGE2, 3 and 4 Genes in Human Cutaneous Melanoma. <i>Journal of Immunotherapy</i> , 2002, 25, 16-26.	2.4	111
47	Recombinant transmembrane CD59 (CD59-TM) confers complement resistance to GPI-anchored protein defective melanoma cells*. <i>Journal of Cellular Physiology</i> , 2002, 190, 200-206.	4.1	7
48	5-aza-2'-deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications. <i>Clinical Cancer Research</i> , 2002, 8, 2690-5.	7.0	114
49	Unbalanced expression of HLA-A and -B antigens: A specific feature of cutaneous melanoma and other non-hemopoietic malignancies reverted by IFN-?. <i>International Journal of Cancer</i> , 2001, 91, 500-507.	5.1	10
50	Endoglin: An accessory component of the TGF- β binding receptor complex with diagnostic, prognostic, and bioimmunotherapeutic potential in human malignancies. <i>Journal of Cellular Physiology</i> , 2001, 188, 1-7.	4.1	162
51	Unbalanced expression of HLA-A and -B antigens: A specific feature of cutaneous melanoma and other non-hemopoietic malignancies reverted by IFN- β . <i>International Journal of Cancer</i> , 2001, 91, 500-507.	5.1	1
52	Overexpression of protectin (CD59) down-modulates the susceptibility of human melanoma cells to homologous complement. <i>Journal of Cellular Physiology</i> , 2000, 185, 317-323.	4.1	26
53	In vitro analysis of the melanoma/endothelium interaction increasing the release of soluble intercellular adhesion molecule 1 by endothelial cells. <i>Cancer Immunology, Immunotherapy</i> , 1999, 48, 132-138.	4.2	8
54	Prolonged Upregulation of the Expression of HLA Class I Antigens and Co stimulatory Molecules on Melanoma Cells Treated with 5-aza-2'-deoxycytidine (5-AZA-CdR). <i>Journal of Immunotherapy</i> , 1999, 22, 16-24.	2.4	119

#	ARTICLE	IF	CITATIONS
55	Phospholipid scramblase 1 as a critical node at the crossroad between autophagy and apoptosis in mantle cell lymphoma. <i>Oncotarget</i> , 0, 7, 41913-41928.	1.8	17